ASCO and EHA 2026 updates on the third-gen TKI olverembatinib

In this SOHO Insider interview from EHA 2026, Elias Jabbour, MD, professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presents different updates from the 2026 ASCO and EHA meetings on the third-generation tyrosine kinase inhibitor olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia.

Watch more from EHA 2026 on SOHO Insider.